jamiethekiller wrote:TIC?

momadance wrote:The 8mg dose is the highest dose given in the trial.

momadance wrote:The 8mg dose is the highest dose given in the trial.

The Dude wrote:Where you seeing stuff about the antibody

Bill McNeal wrote:

momadance wrote:The 8mg dose is the highest dose given in the trial.

I mean, it's weird that they are giving the max dosage of a trial drug to a sitting president less than 24 hours after a positive test right?

The Dude wrote:Where you seeing stuff about the antibody

CalvinBall wrote:So who is in charge of our country right now?

jamiethekiller wrote:Guys, it's happening. He's gonna die. Might even be in a medical coma when he loses on election night.

Any description of 'moderate symtpoms' for a 74 year old obese man is about as bad as we're gonna get.

Edit: I'll add in germophobe too. He has given his immune system zero chance to win

Among the first 275 patients, approximately 56% were Hispanic, 13% were African American and 64% had one or more underlying risk factors for severe COVID-19, including obesity (more than 40%). On average, patients were 44 years of age. In total, 49% of participants were male and 51% were female.

At least 1,300 patients will be recruited into the Phase 2/3 portion of the outpatient trial overall. Patients will be followed for 29 days, with viral shedding in the upper respiratory tract assessed approximately every 2-3 days in the Phase 2 portion of the trial and clinical endpoints assessed via investigator and patient-reported data throughout.

In addition to this trial in non-hospitalized patients, REGN-COV2 is currently being studied in a Phase 2/3 clinical trial for the treatment of COVID-19 in hospitalized patients, the Phase 3 open-label RECOVERY trial of hospitalized patients in the UK and a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals. Recruitment in all 4 trials is ongoing.